ClinicalTrials.gg
Not yet recruitingNCT07854665Updated Oct 28, 2026

Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Tic Disorders/Tourette's Syndrome in Children and Adolescents

An interventional study of Transcutaneous auricular vagus nerve stimulation and Sham stimulation in Tourette Syndrome and Chronic Tic Disorder, sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Tourette Syndrome with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Tourette Syndrome · China.

Planned enrollment
Largest of 10
124 · median 60
Started
2026
with 1 other
No phase
8 of 11
5 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
The First Affiliated Hospital of Zhejiang Chinese Medical University

Among the 11 studies in Tourette Syndrome with a site in China, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 11th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

6 of the 11 studies in Tourette Syndrome with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Tourette Syndrome with a site in China, or all of them as a file.
02

Study summary

The objective of this trial is to evaluate the effect of transcutaneous auricular vagus nerve stimulation compared to sham stimulation in improving chronic tic disorder or Tourette's syndrome in children and adolescents.

Read the detailed description

Participants will be randomly assigned to receive transcutaneous auricular vagus nerve stimulation or sham stimulation. Both interventions will be administered 5 times per week for 8 weeks. Study outcomes will be evaluated at baseline and at weeks 4, 8, and 12.

03

Conditions studied

  • Tourette Syndrome
  • Chronic Tic Disorder

Keywords

  • Transcutaneous Auricular Vagus Nerve Stimulation
  • Randomized Controlled Trial
  • Tourette syndrome
  • Chronic Tic Disorder
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria for Tourette syndrome or chronic motor or vocal tic disorder;
  2. Age ≥6 and \<18 years;
  3. YGTSS-TTS >15, or >10 for participants with motor tics or vocal tics only;
  4. If the participant is taking medication at enrollment, the medication regimen and dosage must have been stable for at least 4 weeks, with no planned changes in medication or dosage during the study;
  5. Has not received any non-pharmacological treatment for tics (e.g., acupuncture, transcranial magnetic stimulation, deep brain stimulation) within the preceding 8 weeks;
  6. Provides written .

Exclusion criteria

Exclusion Criteria

  1. Mental or cognitive disability that would preclude participation in the study;
  2. Ear skin lesions, such as infection or eczema;
  3. An implanted cardiac pacemaker or other electronic medical device;
  4. Severe physical diseases, such as coronary heart disease, , or renal failure;
  5. Current participation in another clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Transcutaneous auricular vagus nerve stimulation

    Participants will receive transcutaneous auricular vagus nerve stimulation five times per week for eight consecutive weeks.

    Device: Transcutaneous auricular vagus nerve stimulation

  • Sham comparator
    Sham stimulation

    Participants will receive sham stimulation five times per week for eight consecutive weeks.

    Device: Sham stimulation

Interventions

  • DeviceTranscutaneous auricular vagus nerve stimulation

    Participants in the transcutaneous auricular vagus nerve stimulation group will receive stimulation at auricular acupoints located within the distribution area of the vagus nerve. A Hwato SDZ-II B electroacupuncture apparatus will be employed, with the two connecting clips of the same output lead attached to the acupoints on the same side. Disperse-dense wave stimulation will be applied, with the intensity adjusted according to the patient's tolerance, and each session will last 30 minutes.

  • DeviceSham stimulation

    Participants in the sham group will receive electrical stimulation at auricular acupoints located outside the distribution area of the vagus nerve, with a current intensity of 0.1 mA. All other procedures will be identical to those of the treatment group.

06

What researchers measure

Primary outcomes

  1. The Yale Global Tic Severity Scale Total Tic Score

    The Yale Global Tic Severity Scale (YGTSS) is a clinician-rated instrument designed to evaluate the severity of motor tics, phonic tics, and overall impairment over the preceding week. Motor and vocal tics are rated independently across five dimensions (number, frequency, intensity, complexity, and interference; range 0-5 each), and the dimension scores are summed to yield separate Motor and Vocal Tic scores (range 0-25 each) as well as a combined YGTSS Total Tic Score (range 0-50), with higher scores indicating greater tic severity. The YGTSS Impairment Rating captures tic-related distress and functional impact (range 0-50). The YGTSS Total Tic Score and the YGTSS Impairment Rating are summed to produce a YGTSS total score (range 0-100), with higher scores indicating greater overall severity.

    Time frame: Week 8 (post treatment).

Secondary outcomes

  1. The Yale Global Tic Severity Scale Total Score

    The Yale Global Tic Severity Scale (YGTSS) is a clinician-rated instrument assessing motor tics, vocal tics, and impairment over the preceding week. Motor and vocal tics are each rated on five dimensions (number, frequency, intensity, complexity, and interference; 0-5 each), yielding Motor and Vocal Tic scores (0-25 each) and a YGTSS Total Tic Score (0-50). The YGTSS Impairment (0-50) is added to the YGTSS Total Tic Score to produce a YGTSS Total Score (0-100), with higher scores indicating greater severity.

    Time frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).

  2. Children's Yale-Brown Obsessive Compulsive Scale

    The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) will be used to assess the severity of obsessive-compulsive symptoms in children and adolescents. The total score of CY-BOCS ranges from 0 to 40, with higher scores indicate greater symptom severity.

    Time frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).

  3. Swanson, Nolan, and Pelham-IV-18

    The Swanson, Nolan, and Pelham Rating Scale version IV (SNAP-IV-18) will be used to assess symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. The total score of SNAP-IV-18 ranges from 0 to 54, with higher scores indicate more severe symptoms.

    Time frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).

  4. Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life

    The Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life (C\&A-GTS-QOL) questionnaire will be used to assess health-related quality of life in children and adolescents with Tourette syndrome. The total score of C\&A-GTS-QOL is typically transformed to a 0-100 scale, with higher scores indicating greater impairment and poorer quality of life.

    Time frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).

Other outcomes

  1. Adverse Events

    An adverse event is any unexpected symptom, sign, or health condition occurring after initiation of study treatment, which may or may not be related to the study intervention. Pre-existing health conditions or diseases will only be considered as adverse events if they worsen after enrollment.

    Time frame: Week 0 (baseline) to week 12.

07

Study locations

1 site
  • The first Affiliated Hospital of Zhejiang Chinese Medical University (FirstZhejiangCMU)
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified participant data will be available from the study PI upon reasonable request after publication.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 65 non-industry interventional studies with no phase under Tourette Syndrome, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 65 studies reached it within 33 months; a quarter within 22 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jul 2027 → Oct 2027 and completion Sep 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Oct 31, 2027was Jul 2027
CompletionEst.
Oct 31, 2027was Sep 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2027→Oct 31, 2027
Oct 28, 2026
Study completion
Sep 30, 2027→Oct 31, 2027
Oct 28, 2026
Eligibility
6 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removed(1)Meet DSM-5 diagnostic criteria for Tourette syndrome or persistent (chronic) motor or vocal tic disorder; (2) Age between 6 and 18 years, regardless of gender; (3) YGTSS-TTS score >15; for participants with only motor or vocal tics, a YGTSS-TTS score >10 is required; (4) If currently on medication, the dosage of tic-related medications must have been stable for the past 4 weeks, and no changes to medication are planned during the study period; (5) No physical therapy or surgical treatment for this condition within the past 8 weeks; (6) The participant's guardian signs an informed consent form, and participants aged 8 years and older sign an appropriate assent document, voluntarily agreeing to participate in the study.
  • AddedMeets the DSM-5 diagnostic criteria for Tourette syndrome or chronic motor or vocal tic disorder;
  • AddedAge ≥6 and <18 years;
  • AddedYGTSS-TTS >15, or >10 for participants with motor tics or vocal tics only;
  • AddedIf the participant is taking medication at enrollment, the medication regimen and dosage must have been stable for at least 4 weeks, with no planned changes in medication or dosage during the study;
  • AddedHas not received any non-pharmacological treatment for tics (e.g., acupuncture, transcranial magnetic stimulation, deep brain stimulation) within the preceding 8 weeks;
  • AddedProvides written informed consent.
Exclusion criteria
  • RemovedPresence of severe mental disorders, such as schizophrenia, bipolar disorder, severe depression, suicide risk, etc., or severe cognitive dysfunction, making it impossible to cooperate with the study; (2) Skin damage, infection, eczema, etc. in the ear area, making treatment impossible; (3) Implanted with cardiac pacemaker, implantable nerve stimulator or other electronic implant devices; (4) Complicated with severe cardiovascular or other important organ diseases; (5) Currently participating in other clinical studies.
  • AddedMental or cognitive disability that would preclude participation in the study;
  • AddedEar skin lesions, such as infection or eczema;
  • AddedAn implanted cardiac pacemaker or other electronic medical device;
  • AddedSevere physical diseases, such as coronary heart disease, malignancy, or renal failure;
  • AddedCurrent participation in another clinical trial.
Oct 28, 2026
Interventions
Added Device: Transcutaneous auricular vagus nerve stimulation·Device: Sham stimulation; removed Device: Transcutaneous Auricular Point Electrical Stimulation·Device: micro-stimulation. Arm changed Transcutaneous Auricular Point Electrical Stimulation→Transcutaneous auricular vagus nerve stimulation. Arms added: Sham stimulation; arms removed: micro-stimulation
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe Yale Global Tic Severity Scale Total Tic ScoreTime frame: baseline (Week 0), during treatment (Week 4), and after treatment (Week 8), with a follow-up period of 4 weeks after the end of treatment (Week 12) → Week 8 (post treatment).
Oct 28, 2026
Secondary outcomes
3 time frame changed, 2 added, 2 removed, 3 description edited
What changed in the outcomes
  • AddedThe Yale Global Tic Severity Scale Total ScoreTime frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
  • RemovedChange in YGTSS-TTS score from baselineTime frame: week 4,week12
  • RemovedChange in YGTSS scores across other dimensions relative to baselineTime frame: week 4,week 8,week 12
  • Time frameChildren's Yale-Brown Obsessive Compulsive ScaleWeek 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
  • Time frameSwanson, Nolan, and Pelham-IV-18Week 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
  • Time frameChild and Adolescent Gilles de la Tourette Syndrome-Quality of LifeWeek 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
  • DescriptionChild and Adolescent Gilles de la Tourette Syndrome-Quality of Life: how it is measured was reworded
  • DescriptionChildren's Yale-Brown Obsessive Compulsive Scale: how it is measured was reworded
  • DescriptionSwanson, Nolan, and Pelham-IV-18: how it is measured was reworded
  • Addedother outcomeAdverse EventsTime frame: Week 0 (baseline) to week 12.
Oct 28, 2026
Title
A Randomized Controlled Clinical Trial of Transcutaneous Auricular Point ElectricalVagus Nerve Stimulation for Improving Symptoms of Chronic Tic Disorders/Tourette's Syndrome in Children/ and Adolescents
Oct 28, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 28, 2026
    Primary completion Jul 30, 2027→Oct 31, 2027
    Study completion Sep 30, 2027→Oct 31, 2027
    Eligibility 6 inclusion criteria added, 1 removed; 5 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removed(1)Meet DSM-5 diagnostic criteria for Tourette syndrome or persistent (chronic) motor or vocal tic disorder; (2) Age between 6 and 18 years, regardless of gender; (3) YGTSS-TTS score >15; for participants with only motor or vocal tics, a YGTSS-TTS score >10 is required; (4) If currently on medication, the dosage of tic-related medications must have been stable for the past 4 weeks, and no changes to medication are planned during the study period; (5) No physical therapy or surgical treatment for this condition within the past 8 weeks; (6) The participant's guardian signs an informed consent form, and participants aged 8 years and older sign an appropriate assent document, voluntarily agreeing to participate in the study.
    • AddedMeets the DSM-5 diagnostic criteria for Tourette syndrome or chronic motor or vocal tic disorder;
    • AddedAge ≥6 and <18 years;
    • AddedYGTSS-TTS >15, or >10 for participants with motor tics or vocal tics only;
    • AddedIf the participant is taking medication at enrollment, the medication regimen and dosage must have been stable for at least 4 weeks, with no planned changes in medication or dosage during the study;
    • AddedHas not received any non-pharmacological treatment for tics (e.g., acupuncture, transcranial magnetic stimulation, deep brain stimulation) within the preceding 8 weeks;
    • AddedProvides written informed consent.
    Exclusion criteria
    • RemovedPresence of severe mental disorders, such as schizophrenia, bipolar disorder, severe depression, suicide risk, etc., or severe cognitive dysfunction, making it impossible to cooperate with the study; (2) Skin damage, infection, eczema, etc. in the ear area, making treatment impossible; (3) Implanted with cardiac pacemaker, implantable nerve stimulator or other electronic implant devices; (4) Complicated with severe cardiovascular or other important organ diseases; (5) Currently participating in other clinical studies.
    • AddedMental or cognitive disability that would preclude participation in the study;
    • AddedEar skin lesions, such as infection or eczema;
    • AddedAn implanted cardiac pacemaker or other electronic medical device;
    • AddedSevere physical diseases, such as coronary heart disease, malignancy, or renal failure;
    • AddedCurrent participation in another clinical trial.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe Yale Global Tic Severity Scale Total Tic ScoreTime frame: baseline (Week 0), during treatment (Week 4), and after treatment (Week 8), with a follow-up period of 4 weeks after the end of treatment (Week 12) → Week 8 (post treatment).
    Secondary outcomes 3 time frame changed, 2 added, 2 removed, 3 description edited
    What changed in the outcomes
    • AddedThe Yale Global Tic Severity Scale Total ScoreTime frame: Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
    • RemovedChange in YGTSS-TTS score from baselineTime frame: week 4,week12
    • RemovedChange in YGTSS scores across other dimensions relative to baselineTime frame: week 4,week 8,week 12
    • Time frameChildren's Yale-Brown Obsessive Compulsive ScaleWeek 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
    • Time frameSwanson, Nolan, and Pelham-IV-18Week 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
    • Time frameChild and Adolescent Gilles de la Tourette Syndrome-Quality of LifeWeek 0, Week 4, Week 8, Week 12 → Week 0 (baseline), week 4, week 8 (post treatment), week 12 (follow-up).
    • DescriptionChild and Adolescent Gilles de la Tourette Syndrome-Quality of Life: how it is measured was reworded
    • DescriptionChildren's Yale-Brown Obsessive Compulsive Scale: how it is measured was reworded
    • DescriptionSwanson, Nolan, and Pelham-IV-18: how it is measured was reworded
    • Addedother outcomeAdverse EventsTime frame: Week 0 (baseline) to week 12.
    Interventions Added Device: Transcutaneous auricular vagus nerve stimulation·Device: Sham stimulation; removed Device: Transcutaneous Auricular Point Electrical Stimulation·Device: micro-stimulation. Arm changed Transcutaneous Auricular Point Electrical Stimulation→Transcutaneous auricular vagus nerve stimulation. Arms added: Sham stimulation; arms removed: micro-stimulation
    Title A Randomized Controlled Clinical Trial of Transcutaneous Auricular Point ElectricalVagus Nerve Stimulation for Improving Symptoms of Chronic Tic Disorders/Tourette's Syndrome in Children/ and Adolescents
    + 7 other changes: index terms, verification date, responsible party, description, conditions, contact details and data sharing statement
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854665
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Responsible party
WangSimeng (Principal Investigator, The First Affiliated Hospital of Zhejiang Chinese Medical University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Simeng Wang, PHD
Contact
18811022134@163.com
8618811022134
Zhiyi Xiong, PHD
Contact
zhiyixiong@foxmail.com
8618811022104

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion